Aridis Pharmaceuticals Book Value 2011-2026 | ARDS

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Aridis Pharmaceuticals

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-24.2 M	-13.1 M	-8.68 M	3.64 M	26.3 M	11.4 M	13.8 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
26.3 M	-24.2 M	1.31 M

Quarterly Book Value Aridis Pharmaceuticals

2023-Q3	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-11.8 M	-24.2 M	-35.8 M	-27.9 M	-20.4 M	-13.1 M	-4.16 M	-13.5 M	-8.56 M	-8.68 M	-8.68 M	-8.68 M	-8.68 M	3.64 M	3.64 M	3.64 M	3.64 M	26.3 M	26.3 M	26.3 M	26.3 M	11.4 M	11.4 M	11.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
26.3 M	-35.8 M	-1.67 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Agenus AGEN	314 M	$ 3.27	-1.8 %	$ 1.17 M	USA
Agios Pharmaceuticals AGIO	1.19 B	$ 29.33	-2.98 %	$ 1.7 B	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Akebia Therapeutics AKBA	32.6 M	$ 1.26	-3.44 %	$ 324 M	USA
Akari Therapeutics, Plc AKTX	22.2 M	$ 0.24	1.1 %	$ 5.73 B	Britain
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Aldeyra Therapeutics ALDX	44.3 M	$ 5.49	0.52 %	$ 330 M	USA
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Alector ALEC	30.6 M	$ 2.26	-7.2 %	$ 233 M	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Aligos Therapeutics ALGS	92.1 M	$ 7.02	-0.21 %	$ 451 M	USA
Alkermes plc ALKS	1.82 B	$ 29.32	-2.61 %	$ 4.83 B	Irlanda
Allogene Therapeutics ALLO	512 M	$ 2.57	-7.73 %	$ 403 M	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Alnylam Pharmaceuticals ALNY	789 M	$ 330.95	-0.59 %	$ 43.4 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
Altimmune ALT	124 M	$ 4.2	-2.55 %	$ 298 M	USA
ALX Oncology Holdings ALXO	114 M	$ 2.11	0.09 %	$ 110 M	USA
Amgen AMGN	90.6 B	$ 387.85	0.03 %	$ 209 B	USA
Amphastar Pharmaceuticals AMPH	789 M	$ 20.22	-0.05 %	$ 945 M	USA
Amarin Corporation plc AMRN	552 M	$ 13.62	-1.3 %	$ 5.55 B	Irlanda
AIM ImmunoTech AIM	40.5 M	$ 0.92	5.25 %	$ 44.2 M	USA
AnaptysBio ANAB	484 M	$ 54.61	-0.8 %	$ 1.55 B	USA
Anika Therapeutics ANIK	271 M	$ 14.44	0.53 %	$ 212 M	USA
ANI Pharmaceuticals ANIP	429 M	$ 75.31	1.91 %	$ 1.45 B	USA
Annexon ANNX	293 M	$ 5.38	-3.93 %	$ 739 M	USA
Annovis Bio ANVS	-7.75 M	$ 2.6	-2.99 %	$ 23.5 M	USA
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Apellis Pharmaceuticals APLS	370 M	$ 20.53	-2.05 %	$ 2.59 B	USA
Aptorum Group Limited APM	11.8 M	$ 0.78	-0.67 %	$ 4.25 M	China
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Aprea Therapeutics APRE	22.7 M	$ 0.88	-3.71 %	$ 3.18 M	USA
Aptevo Therapeutics APVO	4.76 M	$ 7.28	-0.55 %	$ 2.01 M	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Aquestive Therapeutics AQST	-60.2 M	$ 3.99	-0.15 %	$ 346 M	USA
Arcturus Therapeutics Holdings ARCT	241 M	$ 8.11	-1.44 %	$ 219 M	Israel
Ardelyx ARDX	167 M	$ 6.32	-3.54 %	$ 1.52 B	USA
Aileron Therapeutics ALRN	54.4 M	-	10.36 %	$ 9.8 M	USA
argenx SE ARGX	5.5 B	$ 762.51	-0.58 %	$ 25 B	Niderland